The Increasing Importance of Rigorous Real-World Evidence.
作者信息
Yang David D, Nguyen Paul L
机构信息
Department of Radiation Oncology, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Radiation Oncology Program, Boston, MA, USA.
出版信息
JNCI Cancer Spectr. 2022 Aug 10;6(4). doi: 10.1093/jncics/pkac051.
Abstract
摘要
相似文献
1
The Increasing Importance of Rigorous Real-World Evidence.严谨的真实世界证据的重要性日益凸显。
JNCI Cancer Spectr. 2022 Aug 10;6(4). doi: 10.1093/jncics/pkac051.
2
Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice.利伐沙班的真实世界证据：验证临床实践中的安全性和有效性。
Thromb Haemost. 2016 Sep 28;116(Suppl. 2):S13-S23. doi: 10.1160/TH16-06-0485. Epub 2016 Sep 14.
3
Real-world experiences with generating real-world evidence: Case Studies from PCORI's pragmatic clinical Studies program.真实世界证据生成的真实世界经验：来自 PCORI 实用临床研究计划的案例研究。
Contemp Clin Trials. 2020 Nov;98:106171. doi: 10.1016/j.cct.2020.106171. Epub 2020 Oct 7.
4
An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting.在上市后环境中调查药物安全性的真实世界研究的方法学缺陷概述。
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):373-380. doi: 10.1080/14740338.2023.2219892. Epub 2023 May 29.
5
[Real-world data studies of medical products in the context of special healthcare policy: study designs and key considerations].[特殊医疗政策背景下医疗产品的真实世界数据研究：研究设计与关键考量]
Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Jul 10;42(7):1306-1311. doi: 10.3760/cma.j.cn112338-20210201-00085.
6
Association of thrombopoietin-related drugs with thromboembolic events: Mendelian randomization and a real-world study.血小板生成素相关药物与血栓栓塞事件的关联：孟德尔随机化研究及一项真实世界研究
Ther Adv Drug Saf. 2024 Jan 27;15:20420986231224236. doi: 10.1177/20420986231224236. eCollection 2024.
7
Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.利用真实世界证据进行医疗器械的监管批准和覆盖范围评估：景观评估。
Value Health. 2021 Dec;24(12):1792-1798. doi: 10.1016/j.jval.2021.07.003. Epub 2021 Aug 18.
8
Modelling the Long-Term Health Outcome and Costs of Thrombectomy in Treating Stroke Patients with Large Ischaemic Core: Comparison between Clinical Trials and Real-World Data.针对大核心梗死的缺血性脑卒中患者采用取栓治疗的长期健康结局和成本建模：临床试验与真实世界数据的比较。
Cerebrovasc Dis. 2023;52(2):137-144. doi: 10.1159/000525806. Epub 2022 Dec 14.
9
Rigorous Criteria for the Collapse of Nonlinear Cooperative Networks.严格的非线性协同网络崩溃标准。
Phys Rev Lett. 2023 Mar 3;130(9):097401. doi: 10.1103/PhysRevLett.130.097401.
10
Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence.评估真实世界数据质量：患者注册研究质量标准在真实世界数据和真实世界证据中的应用。
Ther Innov Regul Sci. 2020 Mar;54(2):303-307. doi: 10.1007/s43441-019-00058-6. Epub 2020 Jan 6.
引用本文的文献
1
Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies.变革性免疫疗法：揭开基于嵌合抗原受体T细胞（CAR-T）基因疗法的新视野、应对挑战并探索治疗前沿
Immunotargets Ther. 2024 Aug 27;13:413-433. doi: 10.2147/ITT.S474659. eCollection 2024.
2
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.全球免疫肿瘤联合治疗晚期肾细胞癌患者的真实世界结局：ARON-1 研究。
Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27.
本文引用的文献
1
Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.一项IV期肿瘤学试验的真实世界证据预测：地加瑞克与亮丙瑞林安全性对比
JNCI Cancer Spectr. 2022 Aug 10;6(4). doi: 10.1093/jncics/pkac049.
2
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement.提高癌症临床试验中的种族和民族多样性：美国临床肿瘤学会和社区癌症中心协会联合研究声明。
J Clin Oncol. 2022 Jul 1;40(19):2163-2171. doi: 10.1200/JCO.22.00754. Epub 2022 May 19.
3
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.与用于前列腺癌治疗的亮丙瑞林相比，地加瑞克的真实世界心血管结局。
JAMA Netw Open. 2021 Oct 1;4(10):e2130587. doi: 10.1001/jamanetworkopen.2021.30587.
4
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.前列腺癌患者中地加瑞克与亮丙瑞林的心血管安全性：PRONOUNCE 随机试验的主要结果。
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
5
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.地加瑞克与亮丙瑞林治疗晚期前列腺癌的心血管安全性：PRONOUNCE试验研究设计
JACC CardioOncol. 2020 Mar 17;2(1):70-81. doi: 10.1016/j.jaccao.2020.01.004. eCollection 2020 Mar.
6
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.口服瑞戈非尼在晚期前列腺癌中的雄激素剥夺治疗。
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
7
Geographic Distribution of Racial Differences in Prostate Cancer Mortality.前列腺癌死亡率的种族差异的地理分布。
JAMA Netw Open. 2020 Mar 2;3(3):e201839. doi: 10.1001/jamanetworkopen.2020.1839.
8
Comparison of Population-Based Observational Studies With Randomized Trials in Oncology.基于人群的观察性研究与肿瘤学随机试验的比较。
J Clin Oncol. 2019 May 10;37(14):1209-1216. doi: 10.1200/JCO.18.01074. Epub 2019 Mar 21.
9
Real-World Evidence - What Is It and What Can It Tell Us?真实世界证据——它是什么以及能告诉我们什么？
N Engl J Med. 2016 Dec 8;375(23):2293-2297. doi: 10.1056/NEJMsb1609216.
10
Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.促性腺激素释放激素激动剂和拮抗剂相关的心血管发病率。
Eur Urol. 2014 Mar;65(3):565-73. doi: 10.1016/j.eururo.2013.10.032. Epub 2013 Nov 1.
Zotero 插件